Allegro Microsystems 주식 (NASDAQ: ALGM)

에 대한 최신 뉴스 Allegro Microsystems (NASDAQ:ALGM) 주식

Allegro Microsystems

Allegro Microsystems Inc is a designer, developer, fabless manufacturer, and marketer of sensor ICs and application-specific analog power ICs for automotive and industrial markets. Its Sensor IC allows customers to precisely measure motion, speed, position, and current, and Power ICs include high-temperature and high-voltage capable motor drivers, power management, and LED driver ICs. Its products are divided into three categories such as SENSE which includes Current Sensors, Switches and Latches, and Interface ICs among others; REGULATE which includes Regulators, ClearPower Modules, and LED Drivers; and DRIVE which includes BLDC Drivers, Brush DC, and others. Key revenue for the company is generated from Greater China and the rest from the United States, Japan, Europe, and other regions.

Microstrategy, Marathon Digital Holdings, Coinbase, Cleanspark, And Tesla: 5 Stocks On Investors' Radars Today Amid Bitcoin Buzz

Equities

Mid Cap

News

Movers

Trading Ideas

ALGM

BILI

MARA

SBSW

TGTX

지난주 급등한 중형주 8종목 (3월 3일~7일) TG 테라퓨틱스 알레그로 마이크로시스템즈 시바니 스틸워터 하모니 골드 마이닝 빌리빌리 지커 존 윌리 앤 손 마라 홀딩스

빌리빌리·마라홀딩스·지커 등 지난주 급등한 중형주 8종목 (3월 3일~7일)

benzinga_deal_dispatch2

Asset Sales

CSAN

SHEL

SRDX

새로운 소식 라이젠(Raizen)은 쉘(NYSE:SHEL)과 코산(NYSE:CSAN) 간의 브라질 합작 회사로, JP모건을 통해 아르헨티나 석유 정유소와 주유소 네트워크 매각을 추진하고 있다. 블룸버그는 최근 CEO 넬슨 고메스(Nelson Gomes)의 애널리스트와의 실적 발표 전화에서의 발언을 인용하여, 이 회사가 &#34;심층적인&#34; 포트폴리오 개편을 진행 중이라고 보도했다.

딜 디스패치: 틱톡의 시계가 똑딱똑딱, 라이젠이 자산 매각을 탐색, 월그린스의 사기업 전환

Allegro MicroSystems, Inc. - Common Stock

Allegro Microsystems Inc

HC Wainwright &amp; Co. analyst Amit Dayal reiterates Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) with a Buy and maintains $14 price target.

Price Target

Reiteration

Analyst Ratings

GEVO

HC Wainwright & Co. Reiterates Buy on Gevo, Maintains $14 Price Target

This one business day extension is to accommodate the settlement and tendering of shares of AspenTech common stock that may be sold due to the S&amp;P MidCap 400 index change.
S&amp;P Global previously announced that AspenTech will be replaced in the index effective prior to the opening of trading on March 11, 2025.

AZPN

Emerson Extends Expiration Of Its Tender Offer To Acquire Aspen Technology Shares Not Already Owned To 5:00 P.M. Eastern Time On March 11, 2025

Emerson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) today announced that it has extended the expiration of its tender offer to acquire all outstanding shares of common stock of Aspen Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZPN#NASDAQ">AZPN</a>) ("AspenTech") not already owned by Emerson to 5:00 p.m. Eastern Time on March 11, 2025. This one business day extension is to accommodate the settlement and tendering of shares of AspenTech common stock that may be sold due to the S&amp;P MidCap 400 index change. S&amp;P Global previously announced that AspenTech will be replaced in the index effective prior to the opening of trading on March 11, 2025.

Government

Regulations

Emerson Extends AspenTech Tender Offer by One Day to Align With S&P Index Change

Guidance

DSGN

Design Therapeutics Expects Cash And Equivalents Of $245.5M As Of December 31, 2024, To Fund Its Planned Operating Expenses Into 2029

General

TETAA

Telesat And QEST Quantenelektronische Systeme Sign Development Contract For Telesat Lightspeed Aero Flat Panel Antenna

Design Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.28) by 14.29 percent. This is a 14.29 percent decrease over losses of $(0.21) per share from the same period last year.

Earnings

Earnings Beats

Design Therapeutics Q4 2024 GAAP EPS $(0.24) Beats $(0.28) Estimate

GDS Holdings Limited ("GDS Holdings", "GDS" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>, HKEX: 9698))), a leading developer and operator of high-performance data centers in China, today announced that it has entered into definitive agreements to monetize, on a net basis, a 70% equity interest in certain of its data centers, at an implied enterprise value ("EV") to EBITDA multiple of around 13 times. In a first of a kind transaction, GDS is selling a 100% equity interest in certain data center project companies to a private REIT ("P-REIT"), which is a special purpose equity scheme involving the issue of an Asset Backed Security ("ABS"). The ABS is 70% subscribed by top tier institutional investors in China, led by China Life Insurance Company Limited ("China Life"), whilst GDS subscribes for the remaining 30% and retains the rights for on-going operation of the underlying data centers. The ABS will be listed on the Shanghai Stock Exchange as a standardized security product. The P-REIT structure is specifically designed to facilitate an eventual injection of the ABS into a public REIT vehicle ("C-REIT") when qualified.
The total EV for the transaction is up to approximately RMB 2.9 billion. The total equity consideration is up to approximately RMB 1.7 billion, or RMB 1.2 billion net of the 30% reinvestment by GDS in the ABS. GDS will receive net cash proceeds of approximately RMB 500 million at closing. The remaining net cash proceeds of approximately RMB 700 million will be paid when certain milestones are met related to the ramp-up of the underlying data centers. GDS will deconsolidate the data center project companies including existing debt and other net liabilities of around RMB 1.2 billion at closing.

GDS Sells 70% Stake in Data Centers to China Life-Led Group in $400M Deal, Plans Future Public REIT Listing

RGNX

REGENXBIO Plans To Present New Interim Biomarker Data From Phase I/II Portion Of AFFINITY DUCHENNE Trial Of RGX-202 At 2025 MDA Clinical & Scientific Conference

Management

FXNC

First National Corporation Appoints Brad Schwartz As President And CFO

NLSP

NLS Pharmaceutics Issues Shareholder Update: Merger Progress, Pipeline Growth, And 18-Month Financial Runway Detailed

&nbsp;<a href="http://www.nlspharma.com/">NLS Pharmaceutics Ltd.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NLSP#NASDAQ">NLSP</a>), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, today issued a letter to its shareholders.
<a href="https://mma.prnewswire.com/media/2637716/NLS_Pharmaceutics_Logo.html"><img src="https://mma.prnewswire.com/media/2637716/NLS_Pharmaceutics_Logo.jpg" alt="NLS Pharmaceutics Logo" /></a>
Dear Shareholders,
We are thrilled to share the significant progress and strategic milestones NLS Pharmaceutics has achieved, positioning our company for a transformative future in the biotechnology sector.
Strategic Merger with Kadimastem
In November 2024, we announced a definitive merger agreement with <a href="http://www.kadimastem.com/">Kadimastem Ltd.</a>&nbsp;(TASE: KDST) ("Kadimastem"), a clinical-stage cell therapy company specializing in "off-the-shelf" allogeneic cell products for neurodegenerative diseases and diabetes. This merger aims to create a Nasdaq-traded biotechnology company with a robust portfolio of advanced therapies. Both companies' boards of directors have unanimously approved the transaction, with Kadimastem's shareholders recently voting in favor and NLS major shareholders holding approximately 40% of NLSs' common shares having signed support letters for the NLS shareholders' meeting to be convened soon. We currently anticipate closing the merger in the second quarter of 2025, pending effectiveness of NLSs' pending registration statement filed with the Securities and Exchange Commission ("SEC"), Nasdaq approval, NLSs' shareholders' approval and customary closing conditions.&nbsp;
Regulatory Filings and Approvals
We filed a Registration Statement on Form F-4 and subsequent amendment with the SEC, detailing the proposed merger with Kadimastem. This filing is a necessary step toward finalizing the merger and creating a combined entity focused on innovative therapies.&nbsp;In addition, we have submitted an application to list the merged company on Nasdaq under the name of "NucelX Ltd.", with the future ticker of NCEL.
Advancements in Diabetes Treatment
In collaboration with iTolerance Inc., Kadimastem has successfully completed a pre-Investigational New Drug ("pre-IND") meeting with the U.S. Food and Drug Administration ("FDA") for iTOL-102, a potential breakthrough therapy for Type 1 Diabetes. This innovative approach combines Kadimastem's IsletRx cells with iTolerance's immunomodulator, aiming to cure Type 1 Diabetes without the need for lifelong immune suppression.&nbsp;
The diabetes treatment landscape has experienced significant growth, underscored by notable mergers and acquisitions. For instance, Novo Nordisk's acquisition of Inversago Pharma for up to $1.075 billion highlights the strategic emphasis on developing novel therapies for obesity, diabetes, and related metabolic disorders. Similarly, Roche's $2.7 billion acquisition of Carmot Therapeutics reflects their concerted effort to expand into the diabetes and obesity markets. Additionally, Sana Biotechnology has made significant advancements in the diabetes space, with early clinical data suggesting their hypo immune platform could enable insulin production without immunosuppression, positioning them as a potential leader in developing transformative treatments for type 1 diabetes. We believe that these developments underscore the sector's robust growth and the immense potential it holds for innovative treatments.&nbsp;
Furthermore, we are expanding our diabetes treatment strategies beyond GLP-1 therapies. By integrating complementary approaches, we aim to address the multifaceted challenges of diabetes management, including neuroinflammation and metabolic resilience.&nbsp;
Advancements in Neurodegenerative Disease Treatment
Post-merger, we plan to prepare and initiate a Phase IIa multi-site clinical trial of AstroRx&#xAE;, Kadimastem's product candidate for Amyotrophic Lateral Sclerosis (ALS). This trial is slated to commence following the merger's completion, marking significant progress in our neurodegenerative disease treatment pipeline.&nbsp;
Experienced International Leadership Team&nbsp;
We believe that Kadimastem contributes to the merger with its experienced international leadership team and board of directors, and with the teams prior experience developing medicine from the laboratory to the market.&nbsp;For example,&nbsp;Rebif&#xAE;, a blockbuster drug invented by Professor Michel Revel, Chief Scientist at Kadimastem, in his capacity as a scientific investigator at the world-renowned Weizmann Institute of Science, was acquired by Merck Serono. In addition, Ronen Twito, Kadimastem's Executive Chairman and Chief Executive Officer, brings extensive experience working in the U.S. capital market and M&amp;A international market.
Advancements in DOXA R&amp;D Programs
Our promising Dual Orexin Receptor Agonist ("DOXA") platform has made significant strides. The development of AEX-41 and AEX-2 compounds showcases our dedication to addressing unmet needs in sleep-wake disorders. Preliminary studies have yielded promising results, reinforcing our confidence in these compounds' potential to transform patient care.
Additional Pipeline Expansion and Research Initiatives
Our commitment to addressing critical health challenges remains steadfast:
<ul>
<li>Fentanyl Dependence Treatment: We have launched a preclinical program evaluating Mazindol ER as a treatment for fentanyl dependence, aiming to offer a non-opioid alternative in combating the opioid crisis.</li>
<li>Advancing Scientific&nbsp;Research: Our recent submissions to and upcoming poster presentation at the American Society of Clinical Psychopharmacology's 2025 Annual Meeting highlight our commitment to innovative therapeutic strategies and groundbreaking research.</li>
</ul>
Financial Resilience and Growth
We have fortified our financial foundation through strategic initiatives:
Nasdaq &amp; Strong Financial Position
<ul>
<li>We carry zero long-term debt, a rarity among biopharmaceutical companies. This strong financial position provides us with flexibility to execute our strategic goals without financial constraints.</li>
<li>We raised approximately $4.2 million pursuant to private placements in October and December 2024, at a premium to market price. We currently believe that the amounts raised in these private placements has extended our operational runway to approximately 18 months.</li>
<li>This financial stability empowers us to accelerate clinical development, pursue strategic partnerships, and advance our innovative pipeline with confidence.</li>
</ul>
Looking Ahead
The momentum generated by these developments underscores our commitment to delivering life-changing therapies. We aim to capitalize on emerging opportunities within the dynamic biotechnology landscape, driving NLS Pharmaceutics toward a future of unparalleled success.
As we embark on this exciting new chapter, we remain laser-focused on:
<ul>
<li>Building an international, strong, well-balanced pipeline and top-notch biotechnology company</li>
<li>Delivering life-changing therapies for patients worldwide</li>
<li>Expanding our pipeline through innovation &amp; strategic collaborations</li>
<li>Maximizing shareholder value by maintaining a strong financial position</li>
</ul>
We extend our deepest gratitude to our shareholders, partners, and supporters for your trust and commitment. Together, we are building a future of unparalleled success for NLS Pharmaceutics.
Sincerely,
Alex Zwyer Chief Executive Officer &nbsp;

NLS Pharmaceutics Merger With Kadimastem Aims to Create Nasdaq-Traded Biotech Powerhouse With Therapies, Highlights Diabetes, ALS, and Opioid Treatment Advances, Signals Strong Growth Ahead With Clean Balance Sheet

All future vehicles under Geely's Galaxy brand will be equipped with G-Pilot, including the recently launched Galaxy E8 sedan.

ECARX's Skyland Pro Intelligent Driving Solution Will Be Integrated Into Geely's G-Pilot Unified Intelligent Driving System

ATEX

Anterix Launches Its AnterixAccelerator Initiative With Investment Of Up To $250M

Leveraging its differentiated commercial infrastructure, NeoGenomics expects to grow incremental topline revenue with contributions from the acquired business while operational consolidation efforts and synergies are expected to yield substantial annual cost reductions, which will be accretive to AEBITDA starting in 2026.

Health Care

NeoGenomics Acquired Pathline, Strengthening The Company's Commercial Presence In The Northeast U.S., Expanding Its Service Capabilities And Accelerating Growth In Molecular And Hematology-oncology Testing, Deal Terms Were Not Disclosed

NOVA

Sunnova Appoints Paul Mathews As President And Chief Executive Officer

TECH

Bio-Techne Commences Shipping The Leo System, Powered By Simple Western Technology

TSEM

Tower Semiconductor, Innolight Expand Collaboration Utilizing Newest Silicon Photonics Platform, Now In Production And Ramping To High Volume

JP Morgan analyst Mark Murphy upgrades DocuSign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) from Underweight to Neutral and raises the price target from $70 to $75.

Upgrades

DOCU

JP Morgan Upgrades DocuSign to Neutral, Raises Price Target to $75

FCEL

Diversified Energy, FuelCell Energy And TESIAC To Form An Acquisition And Development Company Focus On Net-Zero Power From Natural Gas And Captured Coal Mine Methane

<ul>
<li>Launch-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a 16.9 mmHg reduction in systolic blood pressure, and a 9.1 mmHg placebo-adjusted reduction (p-value &lt; 0.0001) assessed by automated office blood pressure at week 6.</li>
<li>Launch-HTN met a predefined endpoint with lorundrostat 50 mg dose achieving a 19.0 mmHg reduction in systolic blood pressure, and an 11.7 mmHg placebo-adjusted reduction (p-value &lt; 0.0001) assessed by automated office blood pressure at end of treatment, week 12.</li>
<li>Advance-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a highly statistically significant 7.9 mmHg placebo-adjusted reduction assessed by 24hr ABPM at end of treatment, week 12.</li>
<li>Lorundrostat demonstrated a favorable safety and tolerability profile in both pivotal trials</li>
</ul>

Biotech

MLYS

Mineralys Therapeutics Announced Topline Data From Its Pivotal Launch-HTN Phase 3 And Pivotal Advance-HTN Phase 2 Trials Of Lorundrostat For Uncontrolled Hypertension Or Resistant Hypertension, Both Trials Met Its Primary Endpoint

Press Releases

Allegro MicroSystems to Showcase Its Dynamic Sensing and Power Solutions at CES 2025

Allegro MicroSystems to Present Virtually at the 27th Annual Needham Growth Conference on January 16, 2025

Allegro MicroSystems Redefines Sensing with Launch of New Current Sensor ICs in Compact Packages

Allegro MicroSystems to Announce Third Quarter Fiscal 2025 Financial Results

Allegro MicroSystems Reports Third Quarter 2025 Results

Allegro MicroSystems Appoints Dr. Krishna Palepu to its Board of Directors

Allegro MicroSystems to Present at Morgan Stanley's Technology, Media & Telecom Conference on March 4, 2025

Allegro MicroSystems Appoints Mike Doogue as President and Chief Executive Officer

onsemi Proposes to Acquire Allegro MicroSystems for $35.10 Per Share in Cash

Allegro Confirms Receipt of Unsolicited Proposal from onsemi

Astera Labs

Ambarella

Credo Technology Group Holding Ltd - Ordinary Shares

Credo Technology Group

Cirrus Logic

Diodes

First Solar

Himax Technologies, Inc. - American depositary shares, each of which represents two ordinary shares.

Himax Techs

JinkoSolar Holding Company Limited American Depositary Shares (each representing 4 Common Shares)

JinkoSolar Holding Co

Lattice Semiconductor Corporation - Common Stock

Lattice Semiconductor

MACOM Technology Solutions Holdings, Inc. - Common Stock

MACOM Technology Solns

MaxLinear

Universal Display Corporation - Common Stock

Universal Display

ON Semiconductor Corporation - Common Stock

ON Semiconductor

Impinj

Power Integrations

Qorvo

Rigetti Computing

Rambus

Silicon Motion Technology Corporation - American Depositary Shares, each representing four ordinary shares

Silicon Motion Technology

SiTime

Silicon Laboratories, Inc. - Common Stock

Silicon Laboratories

Semtech

Skyworks Solutions

Synaptics

United Microelectronics Corporation (NEW) Common Stock

United Microelectronics

Needham

Morgan Stanley

Barclays

Wells Fargo

지난주 가장 좋은 성과를 낸 중형주 8개는 다음과 같다.
<ol>
<li>TG 테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>): 27.75% 상승했다. 이는 회사가 예상보다 좋은 <a href="https://www.benzinga.com//node/44073261" target="_blank" rel="noreferrer noopener">4분기 매출 실적</a>을 발표한 후 발생한 일이다.</li>
<li>알레그로 마이크로시스템즈 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>): 24.26% 급등했다. 이는 온 세미컨덕터(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>)로부터 주당 35.10달러 인수 제안을 받은 후 발생했다. 이러한 제안은 <a href="https://www.benzinga.com//node/44161052" target="_blank" rel="noreferrer noopener">69억 달러 규모의 기업가치</a>를 암시한다.</li>
<li>시바니 스틸워터 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBSW#NYSE">SBSW</a>): 21.63% 상승했다. 이는 금과 은의 강세 때문일 가능성이 있다.</li>
<li>하모니 골드 마이닝 컴퍼니 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMY#NYSE">HMY</a>): 18.99% 상승했다. 이는 금 가격 상승으로 인한 것이다.</li>
<li>빌리빌리 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>): 18.49% 상승했다.</li>
<li>지커 인텔리전트 테크놀로지 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZK#NYSE">ZK</a>): 16.80% 상승했다. 이는 전체 시장의 강세와 트럼프 대통령이 자동차 관세를 연기할 것이라는 보도로 인한 것이다.</li>
<li>존 윌리 앤 손 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLY#NYSE">WLY</a>): 15.77% 상승했다. 이는 3분기 재무 실적이 예상보다 좋게 나타난 후 발생했다.</li>
<li>마라 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>): 15.09% 상승했다. 이는 비트코인 가격이 다시 90,000달러 이상으로 상승한 후 나타났다.</li>
</ol>
이미지 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

<h2 class="wp-block-heading">새로운 소식</h2>
라이젠(Raizen)은 쉘(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHEL#NYSE">SHEL</a>)과 코산(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSAN#NYSE">CSAN</a>) 간의 브라질 합작 회사로, JP모건을 통해 아르헨티나 석유 정유소와 주유소 네트워크 매각을 추진하고 있다. 블룸버그는 최근 CEO 넬슨 고메스(Nelson Gomes)의 애널리스트와의 실적 발표 전화에서의 발언을 인용하여, 이 회사가 &#8220;심층적인&#8221; 포트폴리오 개편을 진행 중이라고 <a href="https://www.bloomberg.com/news/articles/2025-03-06/raizen-is-said-to-hire-jpmorgan-for-argentina-energy-assets-sale?srnd=phx-deals" target="_blank" rel="noopener">보도</a>했다.
<h2 class="wp-block-heading">블록의 업데이트</h2>
월그린스 부츠 얼라이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>)가 시카모어 파트너스(Sycamore Partners)와의 100억 달러 규모의 거래로 민간 부문으로 진출할 가능성이 커졌다. 이 거래는 월그린스 이사회에서 승인되었으며, 주주들에게 주당 11.45달러의 현금을 제공한다. 퓨처 펀드(The Future Fund LLC)의 게리 블랙이 소셜 미디어에서 &#8220;이 회사는 공개 기업이 되어서는 안 된다고 이전에 이야기한 적이 있다&#8221;고 전했다. 그리고 누가 모든 것을 조종하고 있나? 16.9% 지분을 보유하고 있는 스테파노 페시나(Stefano Pessina) 집행 회장이 이 약국 제국을 <a href="https://www.benzinga.com/markets/equities/25/03/44185847/gary-black-says-walgreens-is-a-company-that-shouldnt-be-public-cites-largest-shareholders-role-in-10-billion-sycamore-deal">공개 시선에서 벗어나게 할</a> 때가 되었다고 명확히 결정했다.
대통령 도널드 트럼프는 미국 국부 펀드가 틱톡의 미국 사업을 인수하기를 원한다. 이는 마치 대출로 허덕이는 대학생에게 개인 제트기를 사라고 제안하는 것과 같다. 미국의 부채는 천문학적이며 트럼프 행정부는 (그들이 말하는) <a href="https://www.benzinga.com/news/25/03/44143475/trumps-u-s-doge-service-claims-65b-in-savings-experts-call-it-smoke-and-mirrors-amid-resignations">이를 줄이는 데 집중</a>하고 있다. 그러나 <a href="https://www.reuters.com/markets/wealth/dealmaker-michael-grimes-expected-lead-new-us-sovereign-wealth-fund-sources-say-2025-03-05/?utm_source=newsletter&amp;utm_medium=email&amp;utm_campaign=newsletter_axiosprorata&amp;stream=top">로이터</a>는 우버 IPO와 트위터 인수를 주도한 경험이 있는 인물인 모건 스탠리의 마이클 그라임스(Michael Grimes)가 미국을 위한 국부 펀드의 설계를 감독하고 있다고 보도했다. 하지만 틱톡의 4월 5일 마감일이 다가오고 있어 시간은 촉박하다. 똑딱똑딱. 말장난 의도.
물론 그때까지 거래가 체결될 수 있지만, 하루하루가 지날수록 이것은 마치 헤일 메리(Hail Mary) 패스처럼 느껴진다. 이번에는 미식축구공을 잡는 대신, 미국이 립싱크와 트렌드를 선도하는 이 소셜 미디어 거인을 잡기를 바라고 있다.
한편, 온세미(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>)가 알레그로 마이크로시스템즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>)에 대한 인수 제안을 주당 35.10달러로 인상해 69억 달러 규모의 거래로 평가되었다. 이는 9월 2일 제출된 초기 제안인 주당 34.50달러보다 증가한 금액이다.
<h2 class="wp-block-heading">블록에서의 거래 중단</h2>
아메리칸 익스프레스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>)가 벨뷰(Bellevue), 워싱턴에 본사를 둔 센터(Center)를 인수하기로 합의했다고 <a href="https://www.bloomberg.com/news/articles/2025-03-06/american-express-to-acquire-expense-management-company-center?srnd=phx-deals" target="_blank" rel="noopener">블룸버그</a>가 보도했다. 센터는 듀러블 캐피털 파트너스, 탑 티어 캐피털 파트너스 및 망고 캐피털이 지원하는 소프트웨어 제공업체이다.
<h2 class="wp-block-heading">파산 블록</h2>
카누(Canoo)는 전기차 스타트업으로, 제대로 출발하지 못한 상황에서 CEO의 도움으로 재부팅되고 있다. 토니 아퀼라(Anthony Aquila)가 카누의 거의 모든 자산을 파산에서 400만 달러 현금으로 인수한다고 <a href="https://techcrunch.com/2025/03/05/canoos-ceo-is-buying-the-bankrupt-ev-startups-assets/">테크크런치</a>가 보도했다. 이 매각은 카누가 금융회사에 빚진 1,100만 달러의 부채를 없앨 것으로 예상된다&#8230; 편리하게도 아퀼라 자신이 운영하는 회사이다. 카누는 불과 6주 전 챕터 7 청산을 신청했다. NASA와 국방부와의 정부 계약은 별다른 성과를 내지 못했다. 이 스타트업은 약 1억 4,500만 달러의 자산이 있지만 1억 7,500만 달러의 부채가 있다. 이제 다른 구매자들도 3월 28일 이전에 경합에 참여할 수 있다.
<h2 class="wp-block-heading">블록에서의 소식</h2>
트럼프의 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41979935/golden-years-for-ma-deals-ahead-under-trump-analysts-highlight-top-10-large-cap-candidates">백악관 복귀</a>와 함께 예상되었던 M&amp;A 거래의 물결은 이렇게 끝나간다.
그들은 <a href="https://in.benzinga.com/news/25/02/44045159/trumps-plan-to-rein-in-regulators-could-erode-market-trust-says-2-3-trillion-asset-manager">규제 완화</a>와 더 <a href="https://www.benzinga.com/25/03/44197558/whats-moving-markets-friday">활기찬 주식 시장</a>을 기대했다. 지금까지 두 가지 시나리오 모두 실현되지 않았다. 딜로직에 따르면, 미국 기반 M&amp;A 거래량은 2024년 같은 시기와 비교해 약 29% 감소했다.
연방 거래 위원회(FTC)의 최근 조치를 고려해보자. 트럼프 임명자가 수장인 이 기관은 사모펀드가 서모딕스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRDX#NASDAQ">SRDX</a>)를 인수하려는 계획에 제동을 걸고 있다. 이 회사는 약물 전달 및 체외(vitro) 진단 기술을 전문으로 한다.
인수자는 GTCR로, 이미 바이오코트(Biocoat)라는 서모딕스의 경쟁사를 보유하고 있다. 두 회사를 모두 소유하게 되면 50% 이상의 시장 지배력을 갖게 되어 경쟁을 억압할 수 있다. 기술 비용이 소비자에게 실제로 부담이 될 것이다. 새로운 경쟁자가 바이오코트와 서모딕스의 콤비에 도전할 가능성이 낮기 때문에 FTC는 이 문제를 일리노이 북부 지방법원에 회부했다.
트럼프 행정부가 이 합병을 간과하지 않는다는 사실에 놀란 분들을 위해 그의 첫 임기에는 법무부가 AT&amp;T와 타임 워너 간의 거래, 싱클레어(Sinclair)와 트리뷴 미디어(Tribune Media) 간의 거래, 브로드컴과 퀄컴 간의 거래, 드래프트킹스와 팬듀얼 간의 거래를 차단한 바 있다.
이제 읽어보세요:
<ul>
<li><a href="https://www.benzinga.com/real-estate/25/03/44110974/halle-berry-launches-a-new-business-venture-succeeds-with-netflix-and-doubles-down-on-her-luxury-malibu-home">할리 베리, 새로운 사업 벤처를 시작하고 넷플릭스와의 성공을 거두며 그녀의 고급 말리부 주택에 투자하다</a></li>
</ul>
지난주의 <a href="https://www.benzinga.com/news/asset-sales/25/02/43897289/deal-dispatch-hooters-plans-restructuring-prada-in-talks-to-acquire-versace">딜 디스패치 에디션을 보려면 여기를 클릭하세요</a>.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Allegro Microsystems

뉴스

에 대한 최신 뉴스 Allegro Microsystems (NASDAQ:ALGM) 주식

일요일, 3월 09, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌